A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-I)
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms SAPPHIRE-I
- Sponsors Abbott Laboratories; AbbVie
- 07 Mar 2018 Results of pooled data from nine clinical trials, were published in the Clinical Pharmacokinetics.
- 01 Dec 2017 Results of post-hoc pooled analysis of this and other five phase III trials, published in the Infectious Diseases and Therapy.
- 04 Apr 2017 Results of exposure-safety response analysis using data (n=2998) from patients of five phase II and six phase III studies (Co-Pilot, Navigator, M13-386, Aviator, M14-103, SAPPHIRE-I, SAPPHIRE-II, TURQUOISE-II, PEARL-II, PEARL-III, PEARL-IV), published in the Clinical Drug Investigation Journal.